JAK2 and neutropenia: Since experimental evidence suggests neutropenia is generally not observed using potent Jak inhibitors in rodents or human patients at doses in which Jak2 is inhibited for less than 8 hours [43,54, 55], CC-509 will be unlikely to induce neutropenia in human patients at exposures predicted to be efficacious.